PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance
- PMID: 24274399
- DOI: 10.2174/1568009613666131126113854
PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance
Abstract
PIM1 kinase is a serine/threonine kinase that has been shown to be overexpressed in multiple human malignancies, including prostate cancer. PIM1 phosphorylates multiple cellular substrates to inhibit apoptosis and promote cell cycle progression. Increased PIM1 can also facilitate genomic instability to promote neoplastic processes. PIM1 kinase is overexpressed in high-grade prostate intraepithelial neoplasia and in prostate cancer compared to normal prostatic tissue and benign prostate hyperplasia. Elevated PIM1 levels have been shown to be the direct result of oncogenic fusion proteins and active signal transduction pathways. In vitro and in vivo mouse studies indicate that PIM1 is weakly tumorigenic but synergizes dramatically when coexpressed with MYC. PIM1 kinase can also phosphorylate the androgen receptor (AR), thereby regulating AR degradation and function, in a low androgen environment. This finding implicates PIM1 in castration -resistant prostate cancer. Furthermore, expression of PIM1 has been shown to be increased in prostate tissue after docetaxel exposure, conferring partial resistance to docetaxel. Correlatively, decreased PIM1 levels sensitize prostate cancer cells to docetaxel treatment. Thus, PIM1 may be a target in docetaxel resistant disease. In summary, PIM1 kinase is involved in prostate tumorigenesis, castration resistance, and docetaxel resistance. Several PIM1 kinase inhibitors have been reported and are in varied stages of drug development. PIM1 is involved in multiple processes in the development and propagation of prostate cancer, thus a PIM1 kinase inhibitor may serve as an effective therapeutic agent in this prevalent disease.
Similar articles
-
Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.Adv Cancer Res. 2015;127:123-58. doi: 10.1016/bs.acr.2015.03.001. Epub 2015 Mar 29. Adv Cancer Res. 2015. PMID: 26093899 Review.
-
PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.J Natl Cancer Inst. 2014 Dec 13;107(2):dju407. doi: 10.1093/jnci/dju407. Print 2015 Feb. J Natl Cancer Inst. 2014. PMID: 25505253 Free PMC article.
-
EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1).Arch Toxicol. 2015 Apr;89(4):591-605. doi: 10.1007/s00204-014-1275-x. Epub 2014 Jun 3. Arch Toxicol. 2015. PMID: 24888374
-
PIM1 kinase as a target for cancer therapy.Expert Opin Investig Drugs. 2012 Apr;21(4):425-36. doi: 10.1517/13543784.2012.668527. Epub 2012 Mar 4. Expert Opin Investig Drugs. 2012. PMID: 22385334 Review.
-
Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.BMC Cancer. 2010 Jun 1;10:248. doi: 10.1186/1471-2407-10-248. BMC Cancer. 2010. PMID: 20515470 Free PMC article.
Cited by
-
Targeting the autophagy-miRNA axis in prostate cancer: toward novel diagnostic and therapeutic strategies.Naunyn Schmiedebergs Arch Pharmacol. 2024 May 18. doi: 10.1007/s00210-024-03153-0. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38761210 Review.
-
Analysis of genetic biomarkers, polymorphisms in ADME-related genes and their impact on pharmacotherapy for prostate cancer.Cancer Cell Int. 2023 Oct 19;23(1):247. doi: 10.1186/s12935-023-03084-5. Cancer Cell Int. 2023. PMID: 37858151 Free PMC article. Review.
-
Identification of novel genetic variants, including PIM1 and LINC01491, with ICD-10 based diagnosis of pulmonary arterial hypertension in the UK Biobank cohort.Front Drug Discov (Lausanne). 2023;3:1127736. doi: 10.3389/fddsv.2023.1127736. Epub 2023 Feb 8. Front Drug Discov (Lausanne). 2023. PMID: 37089865 Free PMC article.
-
Regulation of temozolomide resistance via lncRNAs: Clinical and biological properties of lncRNAs in gliomas (Review).Int J Oncol. 2022 Sep;61(3):101. doi: 10.3892/ijo.2022.5391. Epub 2022 Jul 7. Int J Oncol. 2022. PMID: 35796022 Free PMC article. Review.
-
Targeting DNA topoisomerase IIα (TOP2A) in the hypoxic tumour microenvironment using unidirectional hypoxia-activated prodrugs (uHAPs).IUBMB Life. 2023 Jan;75(1):40-54. doi: 10.1002/iub.2619. Epub 2022 May 2. IUBMB Life. 2023. PMID: 35499745 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials